PT - JOURNAL ARTICLE AU - Dhungel, Binod AU - Shrestha, Upendra Thapa AU - Adhikari, Sanjib AU - Adhikari, Nabaraj AU - Bhattarai, Alisha AU - Pokharel, Sunil AU - Karkey, Abhilasha AU - Limmathurotsakul, Direk AU - Ghimire, Prakash AU - Rijal, Komal Raj AU - Cheah, Phaik Yeong AU - Pell, Christopher AU - Adhikari, Bipin TI - Use of antimicrobials during the COVID-19 pandemic: a qualitative study among stakeholders in Nepal AID - 10.1101/2023.06.23.23291835 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.23.23291835 4099 - http://medrxiv.org/content/early/2023/07/01/2023.06.23.23291835.short 4100 - http://medrxiv.org/content/early/2023/07/01/2023.06.23.23291835.full AB - Introduction The COVID-19 pandemic was a major public health threat and posed tremendous pressure to develop a cure for it. Apart from ongoing efforts in developing vaccines, a lot of empirical treatments were recommended, that may have expedited the use of antimicrobials. The main objective of this study was to explore if and how the pandemic posed pressure on antimicrobials in Nepal using semi-structured interviews (SSIs) among patients, clinicians and drug dispensers.Methods A total of 30 stakeholders (10 each among clinicians, dispensers and COVID-19 patients) were identified purposively and were approached for SSIs. Clinicians and dispensers working in three tertiary hospitals in Kathmandu were first approached and were asked for their support to reach out to COVID-19 patients who were on follow-up at their out-patient department. SSIs were audio recorded, translated and transcribed into English, and were analyzed for thematic synthesis.Results Over-the-counter (OTC) uses of antibiotics were widespread during the pandemic, and were mostly rooted to patients’ attempts to halt the potential severity due to respiratory like illnesses, and the fear of being identified as a COVID-19 patients. Being identified as a COVID-19 patient was feared because of the stigmatization and social isolation. Patients who visited the drug shops and physicians were reported to make demands on specific medicines including antibiotics that may have added pressure among physicians and dispensers. Clinicians reported a degree of uncertainty related to treatment and that may have added pressure to prescribe antimicrobials. All stakeholders, although mostly patients and dispensers with limited understanding of what constitutes antimicrobials and the mechanisms underpinning it reported that the pressure during the pandemic may have added to the adversities such as antimicrobials resistance.Conclusions COVID-19 added a pressure to prescribe, dispense and overuse antimicrobials and may have accentuated the pre-existing OTC use of antimicrobials. Future pandemics including infectious disease outbreaks are major public health incidents that warrant a special caution on inappropriate pressure on antimicrobials. Strict policies related to the use of antimicrobials are urgent to redress their use during normal and pandemic situations.Competing Interest StatementAuthors declare that they have no competing interests. BA serves as an associate editor at PLoS Global Public Health.Funding StatementThe study was funded by Wellcome Trust, UK. For the purpose of Open Access, the author has applied for a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study obtained ethical approval from Oxford Tropical Research Ethics Committee (OxTREC #502-22) and Nepal Health Research Council (Ref#156/2022).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data is available upon request to the Mahidol Oxford Tropical Medicine Research Unit Data Access Committee (http://www.tropmedres.ac/data-sharing) complying with the data access policy (http://www.tropmedres.ac/_asset/file/data-sharing-policy-v1-0.pdf).